Sernova Corp (SEOVF) 0.2488 $SEOVF
Sernova Announces First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Marketwired - Tue Mar 15, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today its financial results for the three months ending January 31, 2016 and provided an overview of recent Company highlights.
SVA.VN: 0.340 (+0.025)
Sernova Honoured as Member of the "2016 TSX Venture 50" and Ranked #4 in Life Sciences and Clean Technologies
Marketwired - Fri Feb 05, 5:00AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has received the ranking of fourth in the category of Life Sciences and Clean Technologies and has been selected as member of the "2016 TSX Venture 50" Companies. This is a prestigious group of top market performers from among the 1,791 companies listed on the Toronto Venture Exchange as of December 31, 2015.
SVA.VN: 0.340 (+0.025)
Sernova Announces Agreement With CCRM to Produce Specialized Cells for the Treatment of Diabetes
Marketwired - Tue Jan 26, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova's licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.
SVA.VN: 0.340 (+0.025)
BUYINS.NET: SVA, AT, CAB, BMRN, CLMT, SWI Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Jan 06, 6:48AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Sernova Corp (NASDAQ:SVA), ATLANTIC POWER CORP (NYSE:AT), CABELAS INCORPORATED (NYSE:CAB), BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), Calumet Specialty Products Partners LP (NASDAQ:CLMT), SolarWinds Inc (NYSE:SWI) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AT: 2.51 (-0.02), SWI: 59.98 (unch), BMRN: 98.81 (+0.61), CAB: 51.45 (-0.04), SVA: 5.88 (+0.03), CLMT: 4.74 (-0.06)
Sernova Corp to Present at the Biotech Showcase(TM) 2016 in San Francisco on January 13, 2016
Marketwired - Wed Jan 06, 5:12AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova's President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California. In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.
SVA.VN: 0.340 (+0.025)
Sernova Awarded Europe's Prestigious Horizon 2020 Grant to Fund Development of Cell-Based Hemophilia Therapeutic Product Into the Clinic
Marketwired - Mon Dec 21, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage regenerative medicine company, announced today that the European Commission's Horizon 2020 program has awarded a EUR5.6M ($8.5M CAD) grant to a consortium consisting of Sernova Corp. and five European academic and private partners to advance development of a GMP clinical grade Factor VIII releasing therapeutic cell product in combination with Sernova's Cell Pouch(TM) for the treatment of severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream.
SVA.VN: 0.340 (+0.025)
SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
ACCESSWIRE - Mon Oct 05, 8:03AM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.
BUYINS.NET: SVA, TKC, BKF, VC, PRTS, GXC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Sep 29, 8:10AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Sernova Corp (NASDAQ:SVA), Turkcell Iletisim Hizmetleri AS (NYSE:TKC), iShares MSCI BRIC Index Fund (NYSE:BKF), Visteon Corp (NYSE:VC), US Auto Parts Network Inc (NASDAQ
RTS), SPDR S&P China ETF (NYSE:GXC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
VC: 70.40 (+1.09), PRTS: 4.12 (-0.03), TKC: 8.67 (unch), SVA: 5.88 (+0.03), GXC: 72.03 (-0.28), BKF: 31.99 (+0.07)
Sernova Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 21, 3:01PM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a leading clinical stage, regenerative medicine company developing biologically compatible, implantable medical device and therapeutic cellular technologies is pleased to announce it has been listed for trading on the OTCQB market exchange in the United States under the symbol "SEOVF".
SVA.VN: 0.340 (+0.025)
Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies
Marketwired - Thu Sep 10, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a license agreement with the University Health Network (UHN) of Toronto, Canada to gain exclusive worldwide rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.
SVA.VN: 0.340 (+0.025)
Sernova Corp. Announces Collaboration with Massachusetts General Hospital to Develop Novel Diabetes Treatment with Funding Support from JDRF
Marketwired - Tue Jul 07, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH), is pleased to announce a research collaboration with Massachusetts General Hospital, supported with funding from JDRF to develop a novel treatment for diabetes.
SVA.VN: 0.340 (+0.025)
Sernova Grants Stock Options
Marketwired - Fri Jun 26, 4:01PM CDT
SERNOVA CORP. (the "Company"
(TSX VENTURE: SVA) announces that, in accordance with the Company's 2015 Incentive Plan, it has granted a total of 625,000 deferred share units to its directors and a total of 2,460,000 incentive stock options to certain officers, employees and consultants of the Company, each such option being exercisable into a common share at a price of $0.26 per share on or before June 25, 2025.
SVA.VN: 0.340 (+0.025)
Sernova Announces First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Marketwired - Tue Mar 15, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today its financial results for the three months ending January 31, 2016 and provided an overview of recent Company highlights.
SVA.VN: 0.340 (+0.025)
Sernova Honoured as Member of the "2016 TSX Venture 50" and Ranked #4 in Life Sciences and Clean Technologies
Marketwired - Fri Feb 05, 5:00AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has received the ranking of fourth in the category of Life Sciences and Clean Technologies and has been selected as member of the "2016 TSX Venture 50" Companies. This is a prestigious group of top market performers from among the 1,791 companies listed on the Toronto Venture Exchange as of December 31, 2015.
SVA.VN: 0.340 (+0.025)
Sernova Announces Agreement With CCRM to Produce Specialized Cells for the Treatment of Diabetes
Marketwired - Tue Jan 26, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova's licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.
SVA.VN: 0.340 (+0.025)
BUYINS.NET: SVA, AT, CAB, BMRN, CLMT, SWI Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Jan 06, 6:48AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Sernova Corp (NASDAQ:SVA), ATLANTIC POWER CORP (NYSE:AT), CABELAS INCORPORATED (NYSE:CAB), BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), Calumet Specialty Products Partners LP (NASDAQ:CLMT), SolarWinds Inc (NYSE:SWI) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AT: 2.51 (-0.02), SWI: 59.98 (unch), BMRN: 98.81 (+0.61), CAB: 51.45 (-0.04), SVA: 5.88 (+0.03), CLMT: 4.74 (-0.06)
Sernova Corp to Present at the Biotech Showcase(TM) 2016 in San Francisco on January 13, 2016
Marketwired - Wed Jan 06, 5:12AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova's President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California. In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.
SVA.VN: 0.340 (+0.025)
Sernova Awarded Europe's Prestigious Horizon 2020 Grant to Fund Development of Cell-Based Hemophilia Therapeutic Product Into the Clinic
Marketwired - Mon Dec 21, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage regenerative medicine company, announced today that the European Commission's Horizon 2020 program has awarded a EUR5.6M ($8.5M CAD) grant to a consortium consisting of Sernova Corp. and five European academic and private partners to advance development of a GMP clinical grade Factor VIII releasing therapeutic cell product in combination with Sernova's Cell Pouch(TM) for the treatment of severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream.
SVA.VN: 0.340 (+0.025)
SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
ACCESSWIRE - Mon Oct 05, 8:03AM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.
BUYINS.NET: SVA, TKC, BKF, VC, PRTS, GXC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Sep 29, 8:10AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Sernova Corp (NASDAQ:SVA), Turkcell Iletisim Hizmetleri AS (NYSE:TKC), iShares MSCI BRIC Index Fund (NYSE:BKF), Visteon Corp (NYSE:VC), US Auto Parts Network Inc (NASDAQ
RTS), SPDR S&P China ETF (NYSE:GXC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: VC: 70.40 (+1.09), PRTS: 4.12 (-0.03), TKC: 8.67 (unch), SVA: 5.88 (+0.03), GXC: 72.03 (-0.28), BKF: 31.99 (+0.07)
Sernova Announces Listing on OTCQB Exchange
Marketwired - Mon Sep 21, 3:01PM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a leading clinical stage, regenerative medicine company developing biologically compatible, implantable medical device and therapeutic cellular technologies is pleased to announce it has been listed for trading on the OTCQB market exchange in the United States under the symbol "SEOVF".
SVA.VN: 0.340 (+0.025)
Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies
Marketwired - Thu Sep 10, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a license agreement with the University Health Network (UHN) of Toronto, Canada to gain exclusive worldwide rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.
SVA.VN: 0.340 (+0.025)
Sernova Corp. Announces Collaboration with Massachusetts General Hospital to Develop Novel Diabetes Treatment with Funding Support from JDRF
Marketwired - Tue Jul 07, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH), is pleased to announce a research collaboration with Massachusetts General Hospital, supported with funding from JDRF to develop a novel treatment for diabetes.
SVA.VN: 0.340 (+0.025)
Sernova Grants Stock Options
Marketwired - Fri Jun 26, 4:01PM CDT
SERNOVA CORP. (the "Company"
(TSX VENTURE: SVA) announces that, in accordance with the Company's 2015 Incentive Plan, it has granted a total of 625,000 deferred share units to its directors and a total of 2,460,000 incentive stock options to certain officers, employees and consultants of the Company, each such option being exercisable into a common share at a price of $0.26 per share on or before June 25, 2025. SVA.VN: 0.340 (+0.025)
